adipose tissue is an abundantly available source of proliferative and multipotent mesenchymal stem cells with promising potential for regenerative therapeutics. We previously demonstrated that both human and mouse adipose-derived stem cells (ascs) can be reprogrammed into induced pluripotent stem cells (ipscs) with efficiencies higher than those that have been reported for other cell types. the asc-derived ipscs can be generated in a feeder-independent manner, representing a unique model to study reprogramming and an important step toward establishing a safe, clinical grade of cells for therapeutic use. In this study, we provide a detailed protocol for isolation, preparation and transformation of ascs from fat tissue into mouse ipscs in feeder-free conditions and human ipscs using feeder-dependent or feeder/xenobiotic-free processes. this protocol also describes how ascs can be used as feeder cells for maintenance of other pluripotent stem cells. asc derivation is rapid and can be completed in <1 week, with mouse and human ips reprogramming times averaging 1.5 and 2.5 weeks, respectively.
IntroDuctIon
Stem cells are ideal and promising sources not only for studying cellular and developmental processes but also for developing regenerative therapeutics. However, many problems remain before these cells can serve as practical sources for clinical applications. The challenges include availability, efficiency, safety and ethical issues. Stem cells present in the human body are usually very limited in number, and protocols to fully optimize their efficiency of purification and use are still under development. These include development of particular cell lines capable of differentiating into clinically suitable cell types 1 , transplantation methods to deliver the cells effectively into desired locations and introduction of personalized traits tailored for individual needs 2 . Safety is another concern because typical cell culture methods make use of animal-sourced products such as serum and mouse feeder cell layers 3 . In addition, cells to be transplanted typically originate from heterologous sources, which can potentially increase the risk of immune rejection 4 . For example, commonly used human embryonic stem cells (ESCs) express an immunogenic nonhuman cell surface modification (sialic acid Neu5Gc), presumably due to the use of animalderived products in culture medium 5 . Furthermore, ethical issues continue to be a matter of debate, especially for the use of human ESCs 6 . Many of these problems, we believe, can potentially be solved by using human adipose-derived stem cells (ASCs; also known as processed lipoaspirate, adipose stromal or adipose tissue-derived mesenchymal stem cells (MSCs)) 7 .
Adipose tissue as a source for stem cells
Adipose tissue is an active endocrine organ that greatly impacts whole body glucose and lipid metabolism 8, 9 . Recently, fat tissue has also attracted increasing attention as a source of stem cells that are potentially beneficial for regenerative medicine 10 . In addition to mature adipocytes, adipose tissue contains relatively abundant progenitor and MSC populations in the stromal vascular fraction (SVF).
It is estimated that as many as 1% of SVF cells are MSCs. In contrast, only 0.001-0.002% of cells in the bone marrow, which is considered a standard hub of adult stem cells, represent MSCs 11 . ASCs and bone marrow-derived MSCs are proliferative and multipotent, having the capacity to differentiate into limited cell types such as adipocytes, osteocytes, chondrocytes and myocytes 12, 13 . MSCs from adipose and bone marrow possess many common cell surface markers, although a precise definition of ASC markers is not well established 14, 15 . It is advantageous to use fat tissue as a potential source for regenerative therapies because the tissue is abundant (particularly in this era of worldwide obesity) and relatively easy to obtain. Liposuction, a procedure to remove excess fat tissue, is among the most common plastic surgeries performed in the United States (http://www.surgery.org/sites/ default/files/statsquickfacts.pdf). Additionally, in contrast to bone marrow-derived MSCs that require initial plating with high density ( >50,000 cells per cm 2 ), ASCs can be seeded at a density as low as 3,000 cells per cm 2 .
Achieving pluripotency from multipotent ASCs
The discovery of the ability to create ESC-like, induced pluripotent stem cells (iPSCs) by introducing four transcription factors into somatic cells dramatically advanced the stem cell field. iPSC generation was first described by Yamanaka and colleagues 16 in mouse in 2006, and isolation of human cells was subsequently reported by a number of groups, including the Yamanaka group [17] [18] [19] [20] . This technology enables not only the study of cell dedifferentiation and differentiation, but also the development of patient-specific cells for disease models and regenerative therapeutics. Unlike ESCs, which are isolated from the blastocysts of an embryo, iPSCs can be derived from adult somatic cells and thus avoid many ethical concerns. We recently investigated if the multipotency of ASCs can be upgraded to pluripotency, by transducing the four standard Feeder-dependent and feeder-independent iPS cell derivation from human and mouse adipose stem cells . Whereas ASCs have limited differentiation capability (e.g., adipocytes, osteoblasts and chondrocytes), pluripotent iPSCs have the potential to differentiate into virtually all cell types in the body under appropriate culture conditions. The resultant iPSCs derived from ASCs exhibit all the characteristics and morphologies of ESCs from the corresponding species 7 . Mouse and human adipose-derived iPSCs are over 5-fold and 100-fold more efficient in reprogramming than mouse and human fibroblasts 7 , respectively, which are the most commonly used cell lines for iPS generation. Importantly, both mouse and human adipose cells are capable of giving rise to iPSCs without the need for feeder cells, a finding also reported by another group 21 . This is at least in part due to the intrinsically high expression of self-renewal supporting factors such as basic fibroblast growth factor (bFGF), vitronectin, fibronectin and leukemia inhibitory factor (LIF) in ASCs 7 . We found that ASCs also have the ability to serve as feeders for other pluripotent stem cell lines. This is a key step toward establishing safe, clinical-grade human iPSC lines because culture of iPSCs typically requires feeder layers of mouse embryonic fibroblasts (MEFs) and use of medium containing animal components such as serum and BSA 3 . By preparing growth-arrested ASCs as autologous feeder cells, it may be possible to use cells from a single patient for both deriving and maintaining iPSCs in an autologous environment absent of animal materials. We believe that generation of human adipose-derived iPSCs in xenobiotic-free conditions will obviate the development of non-human immunogenic surface markers described above. In addition, the use of chemically defined medium will ensure quality control, mitigate sources of biological variability and reduce the risk of animal-derived pathogen contamination, further assuring safety of the cell sources.
Diverse strategies for iPSC development
Several transduction techniques have been reported for developing iPSCs. Retroviral delivery is the first and most extensively used protocol for both mouse and human iPSC derivation 16, 17, 19, 20, [22] [23] [24] [25] . Retrovirus can infect nearly all of the cells and initially induce high transgene expression. The viral transgene is subject to silencing over time, which is followed by induction of endogenous pluripotent genes, such as Oct4 (also known as Pou5f1) and Nanog. It is thought that this feature of the retroviral system accounts for a high reprogramming efficiency and high quality of iPSCs derived by this protocol 26 . Lentiviral delivery has also been commonly used for iPSC generation 18, 21, [27] [28] [29] . However, as lentiviral transgenes are more refractory to silencing than retroviral ones, many lentivirusbased iPSC colonies tend to fail after a couple of passages due to the persistence of exogenous factors. To overcome this problem, a doxycycline-inducible lentiviral system was developed, in which the exogenous genes are directed to downregulate on emergence of iPSC colonies [30] [31] [32] . Because both retrovirus and lentivirus are known to randomly integrate into the host genome and thus increase the risks of insertional mutagenesis, use of non-integrative delivery systems has been explored. Adenovirus does not integrate into the genome and has been successfully used for iPSC production 33, 34 . Several groups have made use of virus-free plasmids with various designs for reprogramming [35] [36] [37] [38] [39] [40] [41] . However, both adenoviral and non-viral vectors give very low efficiencies (e.g., 0.0006% with adenovirus and 0.0015% with plasmids in mouse cells), and due to the transient nature of these delivery systems, repeated transduction procedures are often necessary. The presence of oncogenes, especially c-Myc, in the reprogramming factors is another safety concern in the iPSC technology. It is possible to bypass c-Myc and reprogram with three factors (Oct4, Sox2 and Klf4), but this approach usually results in reduction in derivation efficiencies to less than 10%. An attractive alternative method was reported where c-Myc mutants, N-Myc or L-Myc, all of which are much less tumorigenic, are substituted for wild-type c-Myc and render similar reprogramming efficiencies 27, 42 . Thus, use of the alternative Myc constructs along with three other standard factors may deliver both efficiency and safety.
For iPSC derivation, we prefer the retrovirus system for gene delivery because of its high reprogramming efficiency and maintenance of appropriate pluripotent gene expression levels during the course of the procedure. However, depending on experimental goals, the retroviral method can be replaced by any of the transduction systems described above. In order to reduce the potential transforming risk, L-Myc, N-Myc or mutant c-Myc may be substituted for c-Myc.
Potential applications of ASC-derived iPSCs
The ASC-iPSC system can be used for various applications. Differentiation of ASC-derived iPSCs into clinically useful cell types has great therapeutic implications. The feeder-free nature of the product avoids MEF contamination and thus makes an ideal platform to explore gene, protein and metabolite changes during different cellular reprogramming stages. This is an attractive model to study the development of metabolic pathways, considering the importance of fat cells in endocrine regulation. By collecting ASCs from patients with metabolic disorders and deriving iPSCs, it is possible to study disease etiology at the cellular level and investigate therapeutic options. Banking of iPSC lines may be a promising approach for cell transplantation, because human iPSCs can be established from individuals with comprehensive HLA haplotypes. The abundance of liposuction samples renders them relatively accessible and ideal sources for a prototypic 'iPSC library.' Potential applications go beyond making pluripotent cells. It may be possible to introduce defined factors and 'reprogram' white adipose tissuederived ASCs into other clinically useful cell types such as brown adipocytes, which burn energy and counteract with obesity and insulin resistance 43 . The relative abundance and ease of isolation and derivation of ASCs offer an ideal system for studying the molecular mechanisms of cellular reprogramming and translation of stem cells into cell-based therapies.
Despite a number of useful applications, the current protocol has several limitations. As described above, use of the integrative retroviral vectors and inclusion of the oncogenic gene c-Myc can be a significant safety concern. To overcome this problem, this protocol may be modified to use alternative methods using nonintegrative vectors and non-oncogenic reprogramming genes. The feeder-and xeno-free systems of human iPSC derivation give a low reprogramming efficiency and require a longer period. This could be improved by scaling up the cell numbers and treating with small molecules that have been reported to enhance reprogramming efficiencies [44] [45] [46] .
Controls
Successful retrovirus production of reprogramming factors is essential for generating a high number of mouse and human ASC-derived iPSCs. It is therefore important to use a reporter such as GFP, preferably in the same vector background, to determine the efficiency of the ASC transduction. More than 90% of cells with successful transduction are required to achieve maximum iPSC efficiencies. In order to calculate the reprogramming efficiencies, it is necessary to allocate additional wells for cell counting purposes. It is also important to establish that the iPSCs generated are bona fide pluripotent cells. Thus, it is crucial to compare the newly derived iPSCs with established ESC or iPSC lines that are well characterized.
Experimental design
Here we describe detailed protocols for ASC isolation and subsequent iPSC line derivation 7, 21 . We describe derivation of mouse ASC-derived iPSCs in the feeder-free condition, which produces an approximately 0.25% reprogramming efficiency, and provide methods for the derivation of human ASC-derived iPSCs in feederdependent, feeder-free or xeno-free conditions. The use of ASCs for supporting heterologous pluripotent stem cells as feeders is also described. The feeder-dependent human iPSC generation produces the highest efficiency in the shortest time. Both feederfree and xeno-free approaches avoid MEF contamination and are less laborious than the feeder-dependent technique, although the reprogramming process is substantially slower and less efficient (~1.0% efficiency with feeder cells versus ~0.008% without feeders or xenobiotics). When it is desirable to obtain a clinical grade of cells free from contamination with animal materials throughout the procedure, the xeno-free method should be performed. Establishing appropriate culture conditions (i.e., medium and matrix coats used) and passaging techniques is necessary for each iPSC clone derived in this protocol. 
MaterIals
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CRL-11268).
 crItIcal 293T/17 is a derivative of the 293 human kidney epithelial cell line, which constitutively expresses SV40 large T antigen. Clone 17 was selected specifically for its high transfectability and productivity of infectious retrovirus. We use an in-house 293T cell line that has been selected for ease of transfection and production of lentivirus and retrovirus 47 . Polybrene (10 mg ml , respectively). Use of heat-inactivated FBS is recommended. To prepare 500 ml of the medium, mix 50 ml FBS, 5 ml GlutaMAX, 5 ml NEAA solution and 5 ml penicillin/ streptomycin, and then fill up to 500 ml with DMEM. It can be stored at 4 °C for 4 weeks. Expansion DMEM medium for mouse ASCs To increase growth of mouse ASCs (mASCs), supplement complete DMEM medium with 5 ng ml − 1 basic FGF. Expansion medium can be stored at 4 °C for up to 2 weeks. Medium for human ASCs (hASC medium) While expansion DMEM medium is good for culturing human ASCs, we have found that PromoCell's mesenchymal stem cell growth medium (see REAGENTS) achieves optimum growth in regular culture conditions. For xeno-free conditions, use StemPro MSC SFM XenoFree (Invitrogen; see REAGENTS). Refer to the manufacturer's recommendations for storage conditions.
•
Cell sorting buffer This buffer is composed of DMEM without phenol red, 2% (vol/vol) heat-inactivated FBS and 0.1% (wt/vol) sodium azide. It can be stored at 4 °C for up to 4 weeks. Gelatin-coated culture dishes Add a 0.1% (wt/vol) gelatin solution to coat the dish well, ensuring that the entire bottom surface is coated. Incubate for at least 30 min at 37 °C. Store at 37 °C for up to 5 d. Immediately before cell plating, aspirate the solution. mESC medium (serum base) To prepare 500 ml of serum-based mouse ESC medium, mix 400 ml KO-DMEM, with 75 ml ES cell qualified FBS, 5 ml GlutaMAX, 5 ml nucleotides, 5 ml penicillin/streptomycin, 5 ml NEAA solution, 5 ml diluted β-mercaptoethanol (100×) and 50 µl LIF (from 1 × 10 6 U ml − 1 stock; 1,000 U ml − 1 final). Store mESC medium at 4 °C for up to 1 week. mESC medium (KO-SR base) To prepare 500 ml of mouse ESC medium, mix 400 ml KO-DMEM with 75 ml KO-SR, 5 ml GlutaMAX, 5 ml nucleotides, 5 ml penicillin/streptomycin, 5 ml NEAA solution, 5 ml β-mercaptoethanol (100×) and 50 µl LIF (1,000 U ml − 1 final). Store at 4 °C for up to 1 week. hESC medium To prepare 500 ml of human ESC (hESC) medium, mix 385 ml of DMEM/F-12 base medium with 100 ml KO serum replacement, add 5 ml NEAA solution, 5 ml Glutamax, 5 ml β-mercaptoethanol (100×) and basic FGF/FGF2 to final concentration of 10 ng ml − 1 (add 100 µl of a 50 µg ml 
2|
Add an equal volume of collagenase solution (ml per g weight of fat pads) into one autoclaved scintillation vial for each Petri dish and warm to 37 °C.
3|
Rinse fat pads in HBSS, dry with Kimwipes and place into collagenase solution.
4|
Finely mince the tissue with a sterilized scissor.
5| Shake vials (~100 r.p.m.) in a 37 °C water bath shaker for 30-60 min. Check digests every 10 min and stop the reaction when it is complete.
 crItIcal step The digestion efficiency varies with speed and types of shakers and batches of collagenase used. You should see a separated white fat layer; when the vials settle, the fat layer floats on top of the solution.
? trouBlesHootInG 6| Transfer and filter the digested solution through a 250-µm nylon filter. Then, filter through a 100-µm cell strainer and transfer the filtrate into 15-or 50-ml centrifuge tubes, depending on the volume. Centrifuge at 400g for 5 min at room temperature.
7|
Carefully aspirate the floating layer containing mature adipocytes and aqueous supernatant, leaving the pellet. This pellet is the SVF.
8|
Resuspend the pellet with 10 ml HBSS. Centrifuge again at 400g for 5 min.
9| Repeat
Step 8 three times.
10|
If the pellet appears red, rupture the red blood cells by adding 10 ml erythrocyte lysis buffer and pipette up and down to resuspend the pellet. The solution should become red. Leave for 5 min at room temperature and centrifuge at 400g for 5 min. Aspirate the supernatant.
11|
Resuspend the pellet in 10 ml expansion DMEM medium and add 10 ml solution onto a 10-cm Petri dish.
12|
Incubate at 37 °C in a 5% CO 2 incubator for 1 h. The majority of hematopoietic lineage cells such as monocytes/ macrophages will attach to the Petri dish at this stage.
13|
Transfer nonadherent cells (containing ASC populations) to 10-cm regular culture dishes and incubate at 37 °C in a 5% CO 2 incubator. We typically culture cells isolated from 2 to 3 g fat in a single 10-cm dish.
14|
Change the medium after 24 h. After that, feed cells with 10 ml expansion DMEM medium every 3 d until cells reach ~80% confluency. mASCs should exhibit a large and flat fibroblastic morphology (Fig. 1a) . ? trouBlesHootInG
15|
Aspirate the medium and wash with D-PBS three times. Add a minimum amount of 0.25% (wt/vol) trypsin/EDTA, just barely covering the bottom surface (e.g., 1 ml for 10-cm dishes). Incubate at 37 °C for no longer than 5 min. Gently tap the dish to dislodge the cells and observe by microscope. Ignore firmly adhering cells, if any, as these are often of the hematopoietic lineage. Add an equal amount of expansion DMEM medium to inactivate the trypsin. (ii) Cell sorting may be performed with either magnetic beads or a fluorescence-activated cell sorting (FACS) instrument.
Follow the manufacturer's or FACS facility's protocols specific for magnetic bead separation or FACS sorting. For example, we use the IMag Streptavidin Particles Plus-DM system (see REAGENTS) to get rid of lineage markers by magnetic separation. The antibodies for the lineage markers used are biotinylated anti-mouse CD31 (endothelial), CD45 (hematopoietic) and Ter119 (erythrocytes) 48 . Alternatively, a positive selection for stem cell-specific markers may be performed. These markers include Sca-1, CD24, CD29, CD73, CD90 and CD105. Removing the lineage-positive cells or selecting by stem cell markers at an initial passage may result in a better iPS reprogramming efficiency, but this has not been extensively tested. Nevertheless, we find that passaging unsorted cells two or three times as described in
Step 17A(ii) gives comparable efficiency 7 . The optimal densities depend on the pluripotent cell lines used and need to be empirically determined. (v) Culture for up to 7-10 d using standard feeder-dependent ESC/iPSC culture conditions 22, 36, 49 . retrovirus production • tIMInG 1 week 18| For virus to be used to reprogram cells on feeders or feeder-free, follow the standard method (option A). For xeno-free virus production, follow option B. ! cautIon All work involving active virus supernatants or concentrated virus particles must be performed in an appropriate biological safety cabinet, using adequate personal protection equipment (Biosafety level 2 containment). (ii) When cells reach more than 90% confluence (24-48 h), aspirate the medium, gently wash with 10 ml PBS once, remove PBS, and then add 1 ml of 0.05% (wt/vol) trypsin/EDTA. Incubate for 2 min at room temperature. Gently tap the tissue culture plate from the side to ensure that all cells are detached.
Box 1 | ISoLATIoN oF HUMAN ASCs • tIMInG 5-8 H
Detailed protocols for isolating human cells were previously published in Nature Protocols 54 and other journals 13, [55] [56] [57] . Briefly, the protocol for isolating hASCs is similar to Steps 1-16 for mASCs, except that the working volume is typically much larger. In addition, if lipoaspirate samples are used, no mincing with scissors is necessary as the liposuction procedure itself has the mincing effect of the tissue. Alternatively, hASC lines isolated from fat tissue can be obtained from commercial sources (see REAGENTS). The typical morphology of hASC culture is shown in Figure 1b . Commercially available medium can also be used for hASCs in place of expansion DMEM medium. ! cautIon If human tissue samples are used for ASC isolation, make sure that the procedure is first reviewed and approved by the appropriate Human Subjects Institutional Review Board.
(iii) Add 9 ml of complete DMEM medium and transfer to a 15-ml tube. (ix) Place in a 37 °C, 5% CO 2 incubator overnight. (x) The next day, carefully change the medium (10 ml per 10 cm dish) and incubate at 32 °C in a 5% CO 2 incubator overnight. Although virus is more stable at 32 °C, 37 °C is also acceptable.  crItIcal step Ensure that nearly 100% of cells are transfected by visualizing a reporter construct such as pMX-GFP with fluorescence microscopy. (xi) After ~24 h, carefully collect the viral supernatant (~10 ml) by pipetting and transfer to a 15-ml or 50-ml tube. Add 10 ml of fresh complete DMEM medium to the dish. .  crItIcal step Viral supernatants are not concentrated for ASC infection. The use of fresh virus supernatant generally gives the best result. While pseudotyped retrovirus can be frozen in aliquots at − 80 °C without significant loss of infectivity, avoid repeated freeze-thaw cycles. ? trouBlesHootInG (B) Xeno-free virus production protocol (i) This protocol is identical to Step 18A, except that xeno-free medium such as StemPro MSC SFM XenoFree is used instead of the complete DMEM medium to incubate the 293T cells at 48 h after transfection (at Step 18A(xi)). Carefully wash the cells with D-PBS before the medium change. Virus is thus produced in xeno-free conditions. ipsc derivation 19| Mouse iPSCs can be generated from the ASCs produced in Step 17A(ii) in a feeder-free manner using option A. There are three different methods used for derivation of human iPSC lines from isolated hASCs (Box 1 and Step 17): feeder-dependent derivation (option B), feeder-free derivation (option C) or xeno-free derivation (option D).  crItIcal step Prior training and experience with the basic culturing techniques for hESCs or human iPSCs is essential. ! cautIon Use of human ESCs and iPSCs must be approved by the institutional stem cell research oversight committee or equivalent, and must conform to all relevant regulatory and ethical guidelines.
(a) Mouse ipsc derivation • tIMInG 1-2 weeks (i) Trypsinize or thaw mASCs from
Step 17A(ii) at passages 2-3 and plate 40,000 cells per well in 12-well dishes. Save one well for using GFP virus to check transduction efficiency and another well for counting the initial cell number to calculate reprograming efficiency (Step 19A(v) ). (ii) The following day, the cells should be ~70% confluent. Add fresh retroviral supernatant from Step 18A(xiv) that has been filtered with polybrene added (5 µg ml − 1 ). Use 0.25 ml of each virus supernatant per well in a 12-well dish. Thus, when using the four-factor combination, the total volume will be 1 ml. For the control well, add 1 ml of GFP virus supernatant. colonies will be visible (Fig. 2a) .
 crItIcal step With successful reprogramming, you should be able to see more than 100 colonies per well. Among these, more than 50 colonies should be stained positive for Nanog (see Box 2).
(viii) After 9 d, large, fast-growing reprogrammed colonies are visible (Fig. 2b) . Change medium daily once many colonies are growing. These cells can be manually picked, subcloned, cultured and characterized depending on the purpose of the experiments. See Box 2 for a list of typical characterization experiments. Figure 2c shows typical mouse iPSC colonies. Further details on picking, subcloning and culturing 22 , or characterization 36 of mouse iPSCs can be found in other published protocols.
? trouBlesHootInG (B) Derivation of human ipscs on feeder cells • tIMInG 2-3 weeks
(i) Passage 1 × 10 5 hASCs from Step 17A(ii) per well of a 6-well plate. Incubate overnight at 37 °C in 5% CO 2 .  crItIcal step hASCs must be actively proliferating to achieve robust reprograming. Try to avoid cell cultures that have been passaged more than 4-5 times.
(ii) The following day, to transduce the hASC culture with established retroviral reprogramming factors (Oct4, Sox2, Klf4 and c-Myc, or GFP control), mix equal volumes of freshly prepared (or freshly thawed) supernatants of the four retroviral preparations from Step 18A(xiv) and pre-warm to 32 °C for 5-10 min. Typically, a total volume of 2-4 ml of the combined viral supernatant solution (0.5-1 ml each factor) will be needed to reprogram 1 to 2 × 10 5 hASCs. For control, use 2 ml of the GFP supernatant.  crItIcal step The success of reprogramming depends on access to good virus. Follow the protocol in Step 18 to make it in-house, ideally with the help of experienced personnel, or purchase from a proven vendor. (iii) The cells should be 60-70% confluent. Aspirate the hASC medium and pipette 2-4 ml of the combined and pre- ? trouBlesHootInG (xiv) Colonies selected for subcloning can be expanded, characterized (also see Box 2) and frozen for cryopreservation using the same methodology for hESCs; Follow standard practices for hESCs as previously detailed [49] [50] [51] . Figure 3a shows images of iPSC development at different stages. (D) Derivation of human ipscs in xeno-and feeder-free conditions • tIMInG 3-8 weeks (i) Precoat the culture dishes with humanized xenobiotic-free extracellular matrix, such as CELLstart, according to the manufacturer's instructions. Use xeno-free medium, such as StemPro MSC SFM XenoFree, for derivation and propagation of hASCs.  crItIcal step hASCs must be actively proliferating to achieve robust reprograming. Plan to start the reprogramming experiment as soon as sufficient cells are available, as xeno-free medium typically will not support the same level of expansion. (ii) Use virus produced in xeno-free conditions as described in Step 18B(i) for transducing reprogramming factors. (iii) Follow the protocol described in Step 19C(i-vii) , but with the substitution of xeno-free medium (e.g., NutriStem) for mTeSR1 and xeno-free matrix (e.g., CELLstart) for Matrigel to coat the dishes. Alternatively, synthetic polymer-coated dishes (e.g., Synthemax) can be used, as was recently reported 52, 53 . The percentage of emerging iPSC colonies should be similar to the feeder-free derivation (Step 19C). In general, iPSC colonies derived in the xeno-free condition have a flatter morphology (Fig. 3c) • tIMInG Steps 1-16, isolation of mouse ASCs: 5-7 h
Step 17A, ASC expansion: 1-3 weeks (1-3 passages)
Step 17B, cell sorting of ASCs: 2-5 h
Step 17C, freezing ASCs: 1 h
Step 17D, preparing ASCs for feeder layers: 1 h
Step 18, retrovirus production: 1 week
Step 19A, mouse iPSC derivation: 1-2 weeks (until mechanical picking of iPSCs)
Step 19B, derivation of human iPSCs on feeder cells: 2-3 weeks (until mechanical picking of iPSCs)
Step 19C, derivation of human iPSCs in feeder-free conditions: 3-8 weeks
Step 19D, derivation of human iPSCs in xeno-free conditions: 3-8 weeks antIcIpateD results Isolated ASCs should proliferate well, with a typical doubling period of 2-3 d. ASCs are positive for cell surface antigens Sca-1, CD29, CD73 and CD90, and negative for CD31 and CD45. The CD34 marker is present in the initial culture, but is quickly lost after one or two passages. ASCs are phenotypically and functionally very similar to bone marrow-derived MSCs. The authenticity of the mesenchymal origin of ASCs can be tested by differentiation of these cells into those of the mesodermal cell lineage (i.e., adipocytes, osteoblasts and chondrocytes) by the addition of well-defined standard adipogenesis, osteogenesis and chondrogenesis cocktails, respectively [54] [55] [56] . Mouse iPSCs can be produced from ASCs with an efficiency range of 0.1-0.5%. The presence of MEF feeders during iPSC derivation does not affect the percentage of emerging colonies, but appears to better support the maintenance of selfrenewal of many colonies in the long term. Mouse ASC-derived iPSCs can be stained for pluripotent markers, including alkaline phosphatase, Nanog and SSEA1. At least several good colonies of iPSCs need to be maintained and stored. Mouse iPSCs can be further characterized for their pluripotency by in vitro differentiation through embryoid body formation (1-2 weeks), in vivo differentiation through teratoma formation (2-4 weeks) and/or generation of chimeric mice through injection into blastocyst (1-2 months), see Box 2.
The efficiencies of human iPSC derivation are around 0.5-1.5% in the feeder-dependent condition, and around 0.008% in the feeder-free and xeno-free conditions. However, efficiencies are highly affected by many variables such as retrovirus titer, transduction efficiency, cell viability and proliferation states, choice of medium, growth factors, matrix and feeder cells, etc. It is best to pick and maintain as many colonies as possible to ensure the derivation of iPSCs that have the same morphology 
